When we discuss hit finding as part of the drug discovery process, HTS, Fragment Screening and vHTS are often words that will arise. Hit finding is often thought of in terms of screening the compounds themselves, in whichever way is deemed most appropriate for any given target. But the output from that screen, is not the Hit…That’s just the start of the process. At Sygnature Discovery, we have been working to ensure that the transition from a compound that is selected from the screen as an ‘Active’ , is triaged in a thorough way, to assess technology artefacts, contaminants, non-specific binding and solubility through both chemistry and biology assessment, and be confirmed as a Hit. Using recent data, I will outline the process Sygnature employ to build confidence in screening output and move compounds to the next stage of drug discovery.
To view the video assoicated with this lecture